Organogenesis Holdings Inc.

NASDAQ:ORGO

Drug Manufacturers - Specialty & Generic

Healthcare
$0.85 +3.21%

+$0.08 today

Market cap
$110.75M
Beta
1.33
P/E (TTM)
-1086.7
EPS (TTM)
-$0.00
52W Low $2.04High $7.08

Volume 0.86M

Average 1.49M

ORGO Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Organogenesis Holdings Inc.NASDAQ: ORGO

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of $38.14M rose 60.8% year over year, ahead of the +37.2% change in trailing-twelve-month cost of revenue. Sequentially, it fell 23.6% from the prior quarter. Over 3 fiscal years it compounded at +9.4% a year.

Context

  • Cost of revenue amounted to 24.4% of revenue in FY2025, up 0.4 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +60.8% holds above the trailing-twelve-month pace of +37.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$38.14M-23.6% QoQ
Last fiscal yearDec 2025
$137.52M+18.8% YoY
LTMMar 2026
$151.94M+37.2% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+60.8%——
1 year+18.8%——
3-year CAGR+9.4%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
137.52M USD
Year-over-year change
+18.8%
4-year CAGR
+4.8%

Cost of Revenue vs competitors

How ORGO compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +37.2% is the 2nd highest of 9, against a peer median of +8.4%.
  • Cost of revenue amounts to 29.6% of revenue for ORGO, versus a peer median of 51.1%.
ORGO Competitors
Cost of Revenue for ORGO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNDLSNDL Inc.LTM Mar 2026CA$682.57M CAD+0.2%+6.3%72.8%
VREXVarex Imaging CorporationLTM Apr 2026$569.8M USD+3.9%-1.3%66.4%
EBSEmergent BioSolutions Inc.LTM Mar 2026$376M USD-38.7%-15.3%55.6%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$151.94M USD+37.2%+9.4%29.6%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$146.39M USD+62.5%+68.6%35.0%
ANGOAngioDynamics, Inc.LTM Feb 2026$146.03M USD+12.9%-3.6%46.5%
EOLSEvolus, Inc.LTM Mar 2026$103.98M USD+17.4%+21.1%34.5%
BCYCBicycle Therapeutics plcLTM Mar 2026$71.03M USD-55.3%—111.9%
SIGASIGA Technologies, Inc.LTM Mar 2026$32.49M USD+15.1%+41.7%34.6%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$738K USD———
MNPRMonopar Therapeutics Inc.LTM Mar 2026$0 USD———
Peer median (excluding ORGO) —+8.4%+6.3%51.1%

Competitors are the stored peer set for ORGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue467.36M450.89M433.14M482.04M563.03M
Cost of Revenue114.2M105.02M106.48M115.74M137.52M
Gross Profit353.16M345.87M326.66M366.3M425.51M
Gross Margin75.6%76.7%75.4%76.0%75.6%
Research & Development30.74M39.76M44.38M50.27M44.54M
Selling, General & Admin250.2M283.81M269.75M294.51M326.24M
Operating Expenses280.94M323.57M314.13M367.59M369.64M
Depreciation & Amortization16.68M18.03M23.45M17.03M26.94M
EBITDA87M40.32M36.03M15.76M73.91M
EBITDA Margin18.6%8.9%8.3%3.3%13.1%
Operating Income72.22M22.3M12.53M(1.28M)55.87M
Operating Margin15.5%4.9%2.9%-0.3%9.9%
Interest Income00002.28M
Interest Expense7.24M2.01M2.19M1.54M0
Other Income / Expenses(9.13M)(2.02M)(2.13M)(1.52M)(8.9M)
Income Before Tax63.09M20.28M10.39M(2.81M)46.97M
Pre-Tax Margin13.5%4.5%2.4%-0.6%8.3%
Income Tax Expense(31.12M)4.75M5.45M(3.67M)9.94M
Net Income94.2M15.53M4.95M861K37.03M
Net Margin20.2%3.4%1.1%0.2%6.6%
EPS (Basic)0.730.120.04(0.01)0.16
EPS (Diluted)0.700.120.04(0.01)0.15
Weighted Avg Shares128.33M130.07M131.23M131.67M126.74M
Weighted Avg Shares (Diluted)133.66M132.38M132.75M131.67M130.25M

Organogenesis Holdings Inc.

NASDAQ:ORGO

Intrinsic Alpha fair value

Locked

Current Price

$0.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.